Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials.

Autor: Beck EJ; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sherry AD; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Florez MA; Baylor College of Medicine, Houston, Texas., Kouzy R; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Abi Jaoude J; Department of Radiation Oncology, Stanford University, Stanford, California., Lin TA; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland., Miller AM; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Passy AH; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kupferman GS; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel RR; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Chino F; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Higbie VS; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Parseghian CM; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Overman MJ; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Minsky BD; Division of Radiation Oncology, Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Thomas CR Jr; Department of Radiation Oncology and Applied Sciences, Dartmouth Cancer Center, Geisel School of Medicine, Lebanon, New Hampshire., Tang C; Division of Radiation Oncology, Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Msaouel P; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ludmir EB; Division of Radiation Oncology, Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Aug 01; Vol. 4 (8), pp. 2183-2188.

Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer.

Autor: Fox DA; Margaret M. and Albert B. Alkek Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Bhamidipati D; Division of Cancer Medicine Fellowship Program, The University of MD Anderson Cancer Center, Houston, TX, USA., Konishi T; Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kaur H; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., You N; Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Raghav KPS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ge PS; Department of Gastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Messick C; Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Johnson B; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thomas JV; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shah P; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bednarski BK; Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chang GJ; Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ludford K; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Higbie VS; Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Overman MJ; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: moverman@mdanderson.org.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Nov; Vol. 194, pp. 113356. Date of Electronic Publication: 2023 Sep 22.